- Lisata Therapeutics has entered a global product license agreement with Catalent, granting non-exclusive rights to incorporate Lisata’s certepetide into antibody-drug conjugates (ADCs) using Catalent’s SMARTag® platform.
- Under the collaboration, Lisata may receive over $10 million in milestone payments, as well as revenue sharing on future sales and partnerships.
Lisata Therapeutics, Inc. has announced a global licensing agreement with Catalent, Inc., enabling Catalent to incorporate Lisata’s proprietary certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag® technology platform. Certepetide is an internalizing RGD (“iRGD”) cyclic peptide currently being tested by Lisata for its potential to enhance tumour targeting and penetration in combination cancer therapies.
Under the non-exclusive agreement, Catalent gains worldwide rights to develop and commercialize bioconjugate products containing certepetide and its analogs, including the ability to partner with third parties. Catalent can evaluate the peptide as a payload in clinical studies across multiple ADCs, aiming to create a new class of targeted therapies for difficult-to-treat diseases.
“This collaboration is based on positive preclinical results generated by Catalent’s use of an iRGD peptide as part of its SMARTag® ADC platform. It underscores our mutual belief in certepetide’s broad potential and is another significant step forward in Lisata’s mission to bring transformative therapies to patients.”
Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata
The financial terms include over $10 million in tiered study initiation milestone payments to Lisata, along with revenue sharing on future sales and partnerships. Early preclinical data suggest that integrating iRGD peptides into ADCs may improve efficacy and pharmacokinetics, providing a rationale for this strategic collaboration.
“We are excited about the opportunity to explore iRGD biology as it relates to ADC delivery to the tumour microenvironment. Early data suggest that incorporating iRGD peptides into ADCs improves efficacy and pharmacokinetics, leading us to be optimistic about the potential of iRGD as a novel payload class.”
Catalent’s Penelope Drake, Head of R&D, Bioconjugates
